Trends in peptide drug discovery
By Markus Muttenthaler, G. King, D. Adams, P. Alewood. Nature reviews. Drug discovery, 2021
1,479 citations recorded by the source corpus.
Since the introduction of insulin almost a century ago, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. In this Perspective, we summarize key trends in peptide drug discovery and development, covering the early efforts focused on human hormones, elegant medicinal chemistry and rational design strategies, peptide drugs derived from nature, and major breakthroughs in molecular biology and peptide chemistry that continue to advance the field. We emphasize lessons from earlier approaches that are still relevant today as well as emerging strategies such as integrated venomics and peptide-display libraries that create new avenues for peptide drug discovery. We also discuss the pharmaceutical landscape in which peptide drugs could be particularly valuable and analyse the challenges that need to be addressed for them to reach their full potential. Since the introduction of insulin almost a century ago, more than 80 peptide drugs have been approved for a wide range of diseases. This Perspective summarizes trends in peptide drug discovery, emphasizing lessons from earlier approaches as well as emerging strategies such as integrated venomics and peptide-display libraries. It also analyses the remaining challenges and the pharmaceutical landscape in which peptide drugs are particularly valuable.
Subfields: Molecular Biology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/ad9cc0b7b544a7dffea8345cadef42e81dca9dd6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Nanxi Wang
- Wenping Zhang
- Xurui Cheng
- Xi Wang
- Zhibin Yan
- Rui Wang
- G. Shao
- Caiyun Fu
Citations in the corpus
- Therapeutic peptides: current applications and future directions (2022, background): “High serum fasting peptide YY (3-36) is associated with obesity-associated insulin resistance and type 2 diabetes.”